Physician profile
Bryan G Acree
NPI 1023502358
$1,120.03
in general payments reported to CMS, 2019-2025
18 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.26 · 2021: $26.58 · 2022: $323 · 2023: $388 · 2024: $253 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $307.96 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $212.34 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $128.18 | 2022-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $83.58 | 2023-2025 | |
| Exact Sciences Corporation | $54.57 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $49.38 | 2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $47.34 | 2021-2025 | |
| Organon LLC | $41.33 | 2022-2023 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $37.87 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $30.66 | 2024 | Voquezna |
| Novo Nordisk INC | $20.71 | 2022 | |
| Merck Sharp & Dohme LLC | $19.26 | 2019 | |
| Shield Therapeutics INC | $16.30 | 2023 | Accrufer |
| Janssen Biotech, INC. | $15.22 | 2024 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.54 | 2024 | Xifaxan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $14.50 | 2024 | Slynd |
| Abbvie INC. | $14.27 | 2023 | Vraylar |
| Pfizer INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Acree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.